TELA Bio announced Heather Goetz as its new Chief Executive Officer and director during its second quarter 2026 earnings call, while withdrawing full-year revenue guidance after revenue fell 4 percent to $19.3 million. The company attributed the shortfall primarily to a decline in its OviTex PRS portfolio, driven by a sales pilot that caused confusion and was stopped, along with competitive bundling pressures and longer-than-expected ramp times for new sales representatives. Global OviTex unit volumes grew 12 percent year over year, and international revenue rose 26 percent to $3.8 million, but net loss widened to $11.3 million from $9.9 million a year earlier. TELA Bio ended the quarter with $30.4 million in cash and plans to reduce its cost structure to extend its cash runway.
Tela Bio IncQ2 revenue miss and withdrawal of guidance, with net loss widening to $11.3M.
